Pontifax Management 4 G.P. (20 Sells 4,787,331 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Keros Therapeutics Stock Performance

NASDAQ:KROS opened at $13.83 on Friday. Keros Therapeutics, Inc. has a 52 week low of $9.12 and a 52 week high of $72.37. The firm has a market cap of $561.77 million, a price-to-earnings ratio of 44.61, a P/E/G ratio of 1.78 and a beta of 0.97. The firm’s 50-day simple moving average is $15.28 and its 200 day simple moving average is $14.25.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.38. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. During the same period last year, the firm earned ($1.25) earnings per share. Keros Therapeutics’s revenue for the quarter was up 49002.7% compared to the same quarter last year. Sell-side analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on KROS. HC Wainwright decreased their target price on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Keros Therapeutics in a research report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $30.00.

Institutional Trading of Keros Therapeutics

Several hedge funds have recently modified their holdings of KROS. GAMMA Investing LLC increased its stake in shares of Keros Therapeutics by 7,690.3% in the 1st quarter. GAMMA Investing LLC now owns 2,415 shares of the company’s stock valued at $237,000 after acquiring an additional 2,384 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Keros Therapeutics by 9.3% in the 1st quarter. Rhumbline Advisers now owns 44,669 shares of the company’s stock valued at $455,000 after acquiring an additional 3,802 shares in the last quarter. CWM LLC increased its stake in shares of Keros Therapeutics by 10,157.7% in the 1st quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after acquiring an additional 2,641 shares in the last quarter. Corton Capital Inc. bought a new stake in shares of Keros Therapeutics in the 1st quarter valued at $186,000. Finally, Federated Hermes Inc. increased its stake in shares of Keros Therapeutics by 882.3% in the 1st quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock valued at $12,474,000 after acquiring an additional 1,099,519 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.